Arcturus Therapeutics Holdings Inc. (ARCT) - Q3 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024. Arcturus Therapeutics is a commercial messenger RNA (mRNA) medicines company focused on infectious disease vaccines and rare diseases. A key milestone occurred in September 2024 when the company's COVID-19 vaccine, KOSTAIVE (ARCT-154), became the world's first approved and commercially available self-amplifying RNA (sa-mRNA) vaccine following regulatory approval in Japan.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $41,673 | $45,140 | $129,544 | $135,944 |
| Net Loss | $(6,903) | $(16,222) | $(50,936) | $(18,018) |
| Net Loss Per Share | $(0.26) | $(0.61) | $(1.89) | $(0.68) |
| Operating Expenses | $52,410 | $64,454 | $191,819 | $195,877 |
| Cash & Restricted Cash | $294,063 (as of Sept 30, 2024) | |||
| Debt Outstanding | $0 (Wells Fargo credit line available but undrawn) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 7.7% in Q3 2024 and 4.7% for the nine months ended September 30, 2024, compared to the prior year. The decline is primarily attributed to lower milestone achievements from the CSL Seqirus collaboration in the current period.
- Improved Profitability: Net loss narrowed significantly in Q3 2024 ($6.9M) compared to Q3 2023 ($16.2M), driven by a 23.4% reduction in Research and Development (R&D) expenses.
- R&D Expense Reduction: R&D expenses dropped to $39.1M in Q3 2024 from $51.1M in Q3 2023. This was due to the absence of high manufacturing expenses for Meiji supply batches incurred in 2023, partially offset by increased clinical trial costs.
- Grant Revenue Increase: Grant revenue from the Biomedical Advanced Research and Development Authority (BARDA) increased to $2.9M in Q3 2024 from $1.8M in Q3 2023.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash resources ($294.1M) are sufficient to fund operations for at least the next twelve months. The company has a $50M revolving credit facility with Wells Fargo, extended to April 2026, with no borrowings outstanding.
- Commercialization: KOSTAIVE sales in Japan are expected to commence in Q4 2024. Revenue recognition will be subject to a profit-sharing mechanism where development costs are deducted from sales prior to distribution to Arcturus.
- Pipeline Progress:
- COVID-19: Phase 3 studies demonstrated superior immunogenicity and persistence compared to conventional mRNA vaccines. An updated version targeting the JN.1 lineage was approved in Japan.
- Rare Diseases: Phase 2 studies for ARCT-810 (OTC deficiency) are ongoing. An IND application for ARCT-032 (Cystic Fibrosis) received "Study May Proceed" notification from the FDA in August 2024.
- Material Weaknesses: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2024, due to material weaknesses in internal control over financial reporting. These include deficiencies in IT general controls (user access, change management) and revenue recognition controls regarding collaboration arrangements. Remediation is expected to be completed in fiscal year 2024.
Investor Verification Checklist
- Verify the timeline and magnitude of expected royalty/profit-share payments from KOSTAIVE sales in Japan, given the profit-sharing deduction mechanism.
- Monitor the progress of remediation for the disclosed material weaknesses in internal controls over financial reporting.
- Track the status of the European Medicines Agency (EMA) review for ARCT-154 and potential regulatory approvals in the US.
- Assess the cash burn rate relative to the $294M cash balance to confirm the 12-month liquidity runway.
- Review upcoming clinical data readouts for ARCT-810 (OTC) and ARCT-032 (Cystic Fibrosis) to evaluate pipeline de-risking.